Introduction: The Strange Mirror of Biopharma and Food Biopharma has long viewed itself as the high temple of fermentation. From the earliest recombinant insulin made in E. coli to monoclonal antibodies expressed in CHO cells, the industry has prided itself on scientific rigor, regulatory discipline, and painstaking optimization. Each bioreactor is treated like a cathedral of sterility […]
Tag: CDMO
The Top 10 Traits a Pichia CDMO Must Master to Excel in Biologics Manufacturing
The microbial CDMO space is more competitive than ever. With Pichia (now Komagataella phaffii) gaining traction as a powerful expression system, contract development and manufacturing organizations (CDMOs) must sharpen their gameplan. Here are the top ten traits that separate a great Pichia CDMO from the rest—and a few extras to elevate performance across microbial and yeast-based […]
Reprogramming Biologics: The Next Frontier in Cell-Free and Modular Therapeutic Development
Biologics have long represented the pinnacle of therapeutic complexity—antibodies, recombinant proteins, vaccines, and cell-based products that can alter the course of chronic and life-threatening diseases. Yet, as we enter the second quarter of the 21st century, the field is undergoing a major transformation. This change isn’t just about scale or yield—it’s about flexibility, speed, and programmability. Emerging tools […]